Recursion Cuts Its Tempus Data Fee To $14.0 Million A Year, But Loses The Right To Walk Away

The amended deal adds a year and drops the termination option, while Tempus separately pays $12.0 million to license Recursion's RNA model.

Share
Recursion Cuts Its Tempus Data Fee To $14.0 Million A Year, But Loses The Right To Walk Away

Recursion Pharmaceuticals, which uses AI and automated labs to discover drugs, cut the annual fee on its Tempus oncology-data contract to $14.0 million but gave up its right to terminate the deal for convenience, according to its quarterly report filed Monday. The September amendment also adds a year to the five-year agreement.

Lower fee, longer lock

The November 2023 agreement originally called for annual fees of $22.0 million, then $32.0 million, then $42.0 million for each of the last two payments, settled in cash or Class A shares. The original deal let the company terminate for convenience after the first three years, the filing says.

Under the amendment, Recursion pays $14.0 million a year across the final three payment dates, the third through fifth anniversaries. At least $4.0 million of each payment must be in cash. The rest can be paid in Class A stock, cash or both, at Recursion's election. The amount of de-identified patient records the company can access also shrinks.

The prior quarter's 10-Q described annual payments of $22.0 million to $42.0 million, up to $160.0 million in aggregate.

Tempus pays $12.0 million for an RNA model

In the same month, Recursion licensed its RNA foundation model, called TxFM, to Tempus for use in oncology. The license is non-exclusive and runs two years. Tempus will pay a non-refundable $12.0 million in two $6.0 million installments, the first on signing and the second on the first anniversary. Recursion is recording no revenue on the license, the filing says. Tempus also gives Recursion some pathology records.

Recursion's Tempus record purchases were $5.8 million in the third quarter and $8.9 million for the first nine months, against zero and $49.9 million a year earlier. The company ties the lower nine-month figure to the timing of record purchases.

Funding the burn

Recursion's net loss was $119.0 million in the third quarter, against $162.3 million a year earlier. Cash stood at $561.5 million at September 30. The company has no approved products and has funded itself mainly by selling stock.

Through its TD Cowen at-the-market program, Recursion raised $85.5 million net from 23.7 million Class A shares by September 30, leaving $213.3 million available. On October 16 it completed an underwritten offering of 61.5 million Class A shares for net proceeds of approximately $187.2 million. Recursion's market value was $2.4 billion in Monday trading.

The company says in its earnings release that its cash runway now extends into 2029 and that it expects 2026 cash operating expense of less than $375 million.

Recursion hosts an earnings webinar at 8:00 a.m. ET on Tuesday, November 3.

Sources

More on Recursion Pharmaceuticals

All Recursion Pharmaceuticals (RXRX) coverage →